3/24
08:03 am
imux
Immunic (IMUX) is now covered by Guggenheim. They set a "buy" rating and a $7.00 price target on the stock.
Low
Report
Immunic (IMUX) is now covered by Guggenheim. They set a "buy" rating and a $7.00 price target on the stock.
3/20
08:03 am
imux
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium [Yahoo! Finance]
Low
Report
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium [Yahoo! Finance]
3/20
06:58 am
imux
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next [Yahoo! Finance]
Low
Report
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next [Yahoo! Finance]
3/18
10:32 am
imux
Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference [Yahoo! Finance]
Low
Report
Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference [Yahoo! Finance]
3/10
12:20 pm
imux
Immunic secures European patent for MS drug candidate vidofludimus calcium [Yahoo! Finance]
Medium
Report
Immunic secures European patent for MS drug candidate vidofludimus calcium [Yahoo! Finance]
3/10
06:49 am
imux
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium [Yahoo! Finance]
Low
Report
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium [Yahoo! Finance]
3/10
06:30 am
imux
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Low
Report
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
3/3
06:30 am
imux
Immunic to Participate in Investor Conferences in March
Low
Report
Immunic to Participate in Investor Conferences in March
3/2
08:03 am
imux
Immunic (IMUX) had its price target lowered by HC Wainwright from $8.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Immunic (IMUX) had its price target lowered by HC Wainwright from $8.00 to $5.00. They now have a "buy" rating on the stock.
2/28
03:14 pm
imux
Immunic secures $400M to support late-stage MS trials - ICYMI [Yahoo! Finance]
Low
Report
Immunic secures $400M to support late-stage MS trials - ICYMI [Yahoo! Finance]
2/26
09:20 am
imux
Immunic sets stage for phase 3 MS data readout after $400M financing [Yahoo! Finance]
Low
Report
Immunic sets stage for phase 3 MS data readout after $400M financing [Yahoo! Finance]
2/26
06:39 am
imux
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/26
06:30 am
imux
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Medium
Report
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
2/17
04:53 pm
imux
Immunic closes $200M private placement to fund late-stage MS trials [Yahoo! Finance]
Low
Report
Immunic closes $200M private placement to fund late-stage MS trials [Yahoo! Finance]
2/17
04:05 pm
imux
Immunic Announces Closing of Oversubscribed Private Placement Financing
Low
Report
Immunic Announces Closing of Oversubscribed Private Placement Financing
2/16
05:53 am
imux
Immunic secures $400m fund to support commercial-stage development [Yahoo! Finance]
Low
Report
Immunic secures $400m fund to support commercial-stage development [Yahoo! Finance]
2/14
07:51 pm
imux
Why Immunic (IMUX) Is Up 47.2% After $400 Million MS Push And Leadership Shake-Up [Yahoo! Finance]
Low
Report
Why Immunic (IMUX) Is Up 47.2% After $400 Million MS Push And Leadership Shake-Up [Yahoo! Finance]
2/13
11:33 pm
imux
Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push [Globe and Mail, The (Toronto, Canada)]
Low
Report
Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push [Globe and Mail, The (Toronto, Canada)]
2/13
03:01 pm
imux
Update: Immunic Prices Private Placement, to Seek New CEO; Shares Surge [Yahoo! Finance]
Medium
Report
Update: Immunic Prices Private Placement, to Seek New CEO; Shares Surge [Yahoo! Finance]
2/13
11:44 am
imux
Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push [Yahoo! Finance]
High
Report
Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push [Yahoo! Finance]
2/13
08:25 am
imux
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $8.00 to $4.00. They now have a "buy" rating on the stock.
High
Report
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $8.00 to $4.00. They now have a "buy" rating on the stock.
2/13
06:30 am
imux
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
High
Report
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
2/9
08:04 am
imux
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
2/6
05:33 pm
imux
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
High
Report
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
2/5
06:10 am
imux
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Medium
Report
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.